## PHARMACY BENEFACT

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

## Temporary benefit added to the *Alberta Drug Benefit List* (ADBL)

Due to the unavailability of Depo-Provera 150 mg/ml Injection (DIN 00585092) and Depo-Provera 150 mg/ml Injection (USA) (PIN 09858134) manufactured by Pfizer Canada ULC, Depo-Provera 150 mg/ml Prefilled Syringe (DIN 02523493) manufactured by Pfizer Canada ULC, will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List on **August 14, 2022**.

As of **August 14, 2022**, all claims for Depo-Provera 150 mg/ml Prefilled Syringe (DIN 02523493) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

Due to the unavailability of Jamp-Zolmitriptan ODT 2.5 mg Oral Dispersible Tablet (DIN 02428237) manufactured by Jamp Pharma Corporation, Septa-Zolmitriptan-ODT 2.5 mg Oral Dispersible Tablet (DIN 02428474) manufactured by Septa Pharmaceuticals Inc., and Zomig Rapimelt 2.5 mg Oral Dispersible Tablet (DIN 02243045) manufactured by AstraZeneca Canada Inc., Teva-Zolmitriptan OD 2.5 mg Oral Dispersible Tablet (DIN 02342545) manufactured by Teva Canada Limited, will be considered a temporary benefit for the *ADBL*. This grouping was added to the Critical Supply Product List on **June 15, 2020**.

As of **August 11, 2022**, all claims for Teva-Zolmitriptan OD 2.5 mg Oral Dispersible Tablet (DIN 02342545) will be adjudicated to the price published in the most recent ABCDPL until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

If this situation continues to be a long-term matter, then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* to remain as a benefit.

## Temporary Benefit added to the *Alberta Human Services Drug Benefit Supplement* (HSDBS)

Due to the unavailability of Pediatrix 32 mg/ml Oral Solution (DIN 02027798) manufactured by Teva Canada Limited and Tempra Children's 16 mg/ml Oral Syrup (DIN 00884553) and Tempra D.S. Children's 32 mg/ml Oral Syrup (DIN 00875996) manufactured by Paladin Labs Inc., Children's Tylenol Grape 32 mg/ml Oral Suspension (DIN 02046040) manufactured by McNeil Consumer Healthcare, will be considered a temporary benefit for the *Alberta Human Services Drug Benefit Supplement (HSDBS)*.

continued next page





## PHARMACY BENEFACT

continued from previous page

As there is limited supply of this product, it should be conserved for those patients that are at high need for this specialty formula. Note, quantities dispensed for this product should be limited to help provide equitable access, when possible.

As of **August 15, 2022**, all claims for Children's Tylenol Grape 32 mg/ml Oral Suspension (DIN 02046040) will be adjudicated to the price published in the most recent *ABCDPL* until further notice. The *ABCDPL* is available online at **ab.bluecross.ca/providers/pharmacy-home.php**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free) Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



